MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma

Clinical Cancer Research

Volumn 17, Issue 17, 2011, Pages 5812-5821

  Preis, Meir ^a   Gardner, Timothy B ^a   Gordon, Stuart R ^a   Pipas, J Marc ^a   Mackenzie, Todd A ^b   Klein, Erin E ^a   Longnecker, Daniel S ^a   Gutmann, Edward J ^a   Sempere, Lorenzo F ^a   Korc, Murray ^a,b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 19; GEMCITABINE; LOCKED NUCLEIC ACID; MICRORNA; MICRORNA 10B; MICRORNA 155; MICRORNA 196A; MICRORNA 21; MICRORNA 210; UNCLASSIFIED DRUG;

AGED; ARTICLE; ASPIRATION BIOPSY; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTROLLED STUDY; DNA PROBE; ENDOSCOPIC ECHOGRAPHY; EPITHELIUM CELL; FEMALE; FLUORESCENCE ANALYSIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PANCREAS ADENOCARCINOMA; PANCREAS DUCTAL ADENOCARCINOMA; PANCREAS SURGERY; PRIORITY JOURNAL; PROTEIN ANALYSIS; SURVIVAL TIME; TISSUE SECTION; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IN SITU HYBRIDIZATION; MALE; MICRORNAS; MIDDLE AGED; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 80052445088     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0695     Document Type: Article

References (40)

1. Bilimoria K.Y., Bentrem D.J., Ko C.Y., Ritchey J., Stewart A.K., Winchester D.P., et al. Validation of the 6th edition AJCC Pancreatic Cancer Staging System: Report from the National Cancer Database. Cancer 2007;110:738-744 (Pubitemid 47257648)
2. Preis M., Korc M. Kinase signaling pathways as targets for intervention in pancreatic cancer. Cancer Biol Ther 2010;9:754-763
3. Kahl S., Malfertheiner P. Role of endoscopic ultrasound in the diagnosis of patients with solid pancreatic masses. Dig Dis 2004;22:26-31. (Pubitemid 39070144)
4. Sener S.F., Fremgen A., Menck H.R., Winchester D.P. Pancreatic cancer: A report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999;189:1-7. (Pubitemid 29307735)
5. Lim J.E., Chien M.W., Earle C.C. Prognostic factors following curative resection for pancreatic adenocarcinoma: A population-based, linked database analysis of 396 patients. Ann Surg 2003;237:74-85. (Pubitemid 36622320)
6. Herman J.M., Swartz M.J., Hsu C.C., Winter J., Pawlik T.M., Sugar E., et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: Results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol 2008;26:3503-3510
7. Corsini M.M., Miller R.C., Haddock M.G., Donohue J.H., Farnell M.B., Nagorney D.M., et al. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: The Mayo Clinic experience (1975-2005). J Clin Oncol 2008;26:3511-3516
8. Pipas J.M., Mitchell S.E., Barth R.J. Jr, Vera-Gimon R., Rathmann J., Meyer L.P., et al. Phase I study of twice-weekly gemcitabine and concomitantexternal-beam radiotherapy in patients with adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 2001;50:1317-1322 (Pubitemid 32727811)
9. Locker G.Y., Hamilton S., Harris J., Jessup J.M., Kemeny N., Macdonald J.S., et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313-5327 (Pubitemid 46631379)
10. Sempere L.F., Kauppinen S. Translational implications of microRNAs in clinical diagnostics and therapeutics. In: Bradshaw RA, Dennis EA, editors. Handbook of cell signaling 2nd ed. Oxford, UK: Academic Press; 2009. p. 2965-2981
11. Greither T., Grochola L.F., Udelnow A., Lautenschlager C., Wurl P., Taubert H. Elevated expression of microRNAs 155, 203, 210, and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer 2010;126:73-80.
12. Bloomston M., Frankel W.L., Petrocca F., Volinia S., Alder H., Hagan J.P., et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 2007;297:1901-1908 (Pubitemid 46707844)
13. Szafranska A.E., Doleshal M., Edmunds H.S., Gordon S., Luttges J., Munding J.B., et al. Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clin Chem 2008;54:1716-1724
14. Lee E.J., Gusev Y., Jiang J., Nuovo G.J., Lerner M.R., Frankel W.L., et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 2007;120:1046-1054 (Pubitemid 46214304)
15. Du Rieu M.C., Torrisani J., Selves J., Al Saati T., Souque A., Dufresne M., et al. MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. Clin Chem 2010;56:603-612
16. Hanoun N., Delpu Y., Suriawinata A.A., Bournet B., Bureau C., Selves J., et al. The silencing of microRNA 148a production by DNA hypermethylation is an early event in pancreatic carcinogenesis. Clin Chem 2010;56:1107-1118
17. Hezel A.F., Kimmelman A.C., Stanger B.Z., Bardeesy N., Depinho R.A. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2006;20:1218-1249 (Pubitemid 43727584)
18. Sempere L.F., Preis M., Yezefski T., Ouyang H., Suriawinata A.A., Silahtaroglu A., et al. Fluorescence-based codetection with protein markers reveals distinct cellular compartments for altered MicroRNA expression in solid tumors. Clin Cancer Res 2010;16:4246-4255
19. Ma L., Teruya-Feldstein J., Weinberg R.A. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007;449:682-688 (Pubitemid 47552092)
20. Tian Y., Luo A., Cai Y., Su Q., Ding F., Chen H., et al. MicroRNA-10b promotes migration and invasion through KLF4 in human esophageal cancer cell lines. J Biol Chem 2010;285:7986-7994
21. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247
22. Kloppel G., Adsay N.V. Chronic pancreatitis and the differential diagnosis versus pancreatic cancer. Arch Pathol Lab Med 2009;133:382-387
23. Callery M.P., Chang K.J., Fishman E.K., Talamonti M.S., William Traverso L., Linehan D.C. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: Expert consensus statement. Ann Surg Oncol 2009;16:1727-1733
24. Pipas J.M., Barth R.J. Jr, Zaki B., Tsapakos M.J., Suriawinata A.A., Bettmann M.A., et al. Docetaxel/Gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma. Ann Surg Oncol 2005;12:995-1004. (Pubitemid 41660675)
25. Pipas J.M., Zaki B., Suriawinata A.A., Tsapakos M.J., Ripple G.H., Colacchio T.A., et al. Cetuximab, intensity-modulated radiotherapy (IMRT), and twice-weekly gemcitabine for pancreatic adenocarcinoma. J Clin Oncol 2006;24 Suppl:18S.
26. Network NCC. NCCN clinical practice guidelines in oncology: pancreatic adenocarcinoma [cited 2010]. Available from: http://www.nccn.org/professionals/ physician-gls/f-guidelines.asp.
27. Gillen S., Schuster T., Meyer Zum Buschenfelde C., Friess H., Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: A systematic review and meta-analysis of response and resection percentages. PLoS Med 2010;7:e1000267.
28. Artinyan A., Anaya D.A., McKenzie S., Ellenhorn J.D., Kim J. Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma. Cancer 2011;117:2044-2049
29. Garzon R., Garofalo M., Martelli M.P., Briesewitz R., Wang L, Fernandez- Cymering C, et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci U S A 2008;105:3945-3950 (Pubitemid 351723504)
30. Ladeiro Y., Couchy G., Balabaud C., Bioulac-Sage P., Pelletier L., Rebouissou S., et al. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 2008;47:1955-1963 (Pubitemid 351952843)
31. Jukic D.M., Rao U.N., Kelly L., Skaf J.S., Drogowski L.M., Kirkwood J.M., et al. MicroRNA profiling analysis of differences between the melanoma of young adults and older adults. J Transl Med 2010;8:27.
32. SasayamaT., NishiharaM.,Kondoh T.,Hosoda K.,Kohmura E. MicroRNA- 10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC. Int J Cancer 2009;125:1407-1413
33. Ma L., Reinhardt F., Pan E., Soutschek J., Bhat B., Marcusson E.G., et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol 2010;28:341-347
34. Bourguignon L.Y., Wong G., Earle C., Krueger K., Spevak C.C. Hyaluronan- CD44 interaction promotes c-Src-mediated twist signaling, microRNA-10b expression, and RhoA/RhoC upregulation, leading to Rho-kinase-associated cytoskeleton activation and breast tumor cell invasion. J Biol Chem 2010;285:36721-36735
35. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-3988 (Pubitemid 36418143)
36. Moriarty C.H., Pursell B., Mercurio A.M. miR-10b targets Tiam1: Implications for Rac activation and carcinoma migration. J Biol Chem 2010;285:20541-20546
37. Eloubeidi M.A., Chen V.K., Eltoum I.A., Jhala D., Chhieng D.C., Jhala N., et al. Endoscopic ultrasound-guided fine needle aspiration biopsy of patients with suspected pancreatic cancer: Diagnostic accuracy and acute and 30-day complications. Am J Gastroenterol 2003;98:2663-2668 (Pubitemid 38020105)
38. Torrisani J., Bournet B., Du Rieu M.C., Bouisson M., Souque A., Escourrou J., et al. let-7 MicroRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression. Hum Gene Ther 2009;20:831-844
39. Fujita H., Ohuchida K., Mizumoto K., Itaba S., Ito T., Nakata K., et al. High EGFR mRNA expression is a prognostic factor for reduced survival in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Int J Oncol 2011;38:629-641
40. Fujita H., Ohuchida K., Mizumoto K., Itaba S., Ito T., Nakata K., et al. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Neoplasia 2010;12:807-817